NL-OMON50068已完成不适用
tilizing magnetic nanoparticles in prostate cancer for sentinel and aberrant lymph node mapping - Extensive sentinel lymph node mapping
niversitieit Twente0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Adults 18 years and older with a >=cT1N0M0 cinically significant prostate tumour
- •classification and who are scheduled for a prostatectomy
排除标准
- •Contra-indications for robot assisted laparoscopy, intolerance/hypersensitivity
- •to iron or dextran compounds or Magtrace®, patients with an iron overload
- •disease, patients with pacemakers or other implantable devices in the chest
- •wall and/or lower body. Also prostate cancer patients without excessable rectum
研究者
相似试验
已完成
早期 1 期
Magnetic Nanoparticle Thermoablation-Retention and Maintenance in the Prostate:A Phase 0 Study in MenProstate CancerNCT02033447University College London Hospitals12
已完成
2 期
Sentinel Node Biopsy using Magnetic Nanoparticles: A prospective multicentre phase II non-randomised clinical trial to compare sentinel node biopsy using magnetic nanoparticles vs. standard techniqueNL-OMON40081King's College London75
已完成
不适用
SentiMAG multicentre trialMalignant neoplasm of breastBreast CancerCancerISRCTN35827879King's College London (UK)160
进行中（未招募）
1 期
Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?Metastatic prostate cancerEUCTR2022-003788-13-FIHeikki Minn40
进行中（未招募）
1 期
Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?Prostate cancerCTIS2024-511104-16-00Turku University Hospital40